Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-22
2011-03-22
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S222000, C546S188000, C514S316000
Reexamination Certificate
active
07910607
ABSTRACT:
Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the products formed from the adducts after administration.
REFERENCES:
patent: 2004/0024025 (2004-02-01), Kasid et al.
Ivanov, I. et al.: Alkylating spin labels for spin-labelling of DNA. Int. J. Biochem., vol. 15, pp. 433-437, 1983.
Suwalsky, M. et al., “The Anticancer Drug Chlorambucil Interacts with the Human Erythrocyte Membrane and Model Phospholipid Bilayers,” Zeitschrift fur Naturforschung, 54(12):1089-1095 (1999).
Masta, A. et al., “Nitrogen Mustard Inhibits Transcription and Translation in a Cell Free System,” Nucleic Acids Research, 23(17):3508-3515 (1995).
Kohn, K. et al., “Mechanisms of DNA Sequence Selective Alkylation of Guanine-N7 Positions by Nitrogen Mustards,” Nucleic Acid Research, 15(24):10531-10549 (1987).
Yang, X. et al., “P-Glycoprotein Expression in Ovarian Cancer Cell Line Following Treatment with Cisplatin,” Oncology Research, 7(12):619-24 (1995).
Kundu, G. et al., “The Alkylating Properties of Chlorambucil,” Pharmacology Biochemistry and Behavior, 49 (3):621-24 (1994).
Passagne, I. et al., “O6-Methylguanine DNA-methyltransferase (MGMT) Overexpression in Melanoma Cells Induces Resistance to Nitrosoureas and Temozolomide but Sensitizes to Mitomycin C,” Toxicology and Applied Pharmacology, 211(2):97-105 (2006).
Munson, A.E. et al., “Synergistic Lethal Action of Alkylating Agents and Sodium Pentobarbital in the Mouse,” Pharmacology, 11(4):231-40 (1974).
Gupta, V.S. et al., “Reaction of Bifunctional Alkylating Agents with Tetrahydrofolate,” Biochemistry, 6(7):2159-2168 (1967).
Hall, M.D. et al., “Comparative Efficacy of Novel Platinum(IV) Compounds with Established Chemotherapeutic Dugs in Solid Tumour Models,” Biochemical Pharmacology, 67:17-30 (2004).
Rad, A.N. et al., “The Differential Influence of Allogeneic Tumor Cell Death via DNA Damage on Dendritic Cell Maturation and Antigen Presentation,” Cancer Research 63:5143-5150 (2003).
Pandya, U. et al., “Activity of Allelic Variants of Pi Class Human Glutathione S-transferase Toward Chlorambucil,” Biochemical and Biophysical Research Communications 278:258-62 (2000).
Mahoney, B.P. et al., “Tumor Acidity, Ion Trapping and Chemotherapeutics I. Acid pH Affects the Distribution of Chemotherapeutic Agents in vitro,” Biochemical Pharmacology 66:1207-1218 (2003).
Helliger, W. et al., “Differential Sensitivity of Histone Acetylation in Nitrogen-Mustard Sensitive and Resistant Cells. Relation to Drug Uptake, Formation and Repair of DNA-interstrand Cross-links,” Eur J Cancer Clin Oncol 24 (12):1861-1868 (1988).
Lee, M. et al., “Design, Synthesis and Biological Evaluation of DNA Sequence and Minor Groove Selective Alkylating Agents,” Anti-Cancer Drug Design, 8:173-192 (1993).
Sladek, N.E., “Cytotoxic Activity of Alkylating Agents in the Presence of Centrophenoxine and its Hydrolysis Products,” Journal of Pharmacology and Experimental Therapeutics, 203(3):630-639 (1977).
Poot, M. et al., “Cytostatic Synergism Between Bromodeoxyuridine, Bleomycin, Cisplatin and Chlorambucil Demonstrated by a Sensitive Cell Kinetic Assay,” Biochemical Pharmacology, 41(12):1903-1909 (1991).
Zhang, J. et al., “Metabolism of Chlorambucil by Rat Liver Microsomal Glutathione S0transferase,” Chemico-Biological Interactions, 149:61-67 (2004).
Hall, A.G. et al., “Mechanism of Action of, and Modes of Resistance to, Alkylating Agents Used in the Treatment of Haematological Malignancies,” Blood Reviews, 6:163-173 (1992).
Mattes, W.B. et al., “GC-rich Regions in Genomes as Targets for DNA Alkylation,” Carcinogenesis, 9(11):2065-2072 (1988).
Bishop, J.B. et al., “Alterations in the Reproductive Patterns of Female Mice Exposed to Xenobiotics,” Fundamental and Applied Toxicology, 40:191-204 (1997).
Van Putten, L.M. et al., “Factors Determining Cell Killing by Chemotherapeutic Agents in vivo—II. Melphalan, Chlorambucil and Nitorgen Mustard,” Europ J Cancer 7:11-16 (1970).
Bramson, J. et al., “Nitrogen Mustard Drug Resistance B-cell Chronic Lymphocytic Leukemia as an in vivo Model for Crosslinking Agent Resistance,” Mutation Research, 336:269-78 (1995).
Drablos, F. et al., “Alkylation Damage in DNA and RNA—Repair Mechanisms and Medical Significance,” DNA Repair 3:1389-1407 (2004).
Vogel, E.W. et al., “Heritable and Cancer Risks of exposures to Anticancer Drugs: Inter-species Comparisons of Covalent Deoxyribonucleic Acid-binding Agents,” Mutation Research 400:509-540 (1998).
Shinohara, K. et al., “Mechanism of Inhibition of Red Blood Cell Glutathione Reductase Activity by BCNU (1,3-bis(2-chloroethyl)-1-Nitrosourea),” Clinica Chimica Acta 92:147-152 (1979).
Grunicke, H. et al., “Plasma Membrane as Target of Alkylating Agents,” Advances in Enzyme Regulation, 24:247-61 (1985).
Lewis, F.B. et al., “X-radiation and Alkylating Agents as Possible ‘Trigger’ Mechanisms in the Autoimmune Complications of Malignant Lymphoproliferative Disease,” Clin Exp Immunol 1:3-11 (1966).
Johnston, J.B. et al., “Role of the TRAIL/APO2-L Death Receptors in Chlorambucil and Fludarabine-induced Apoptosis in Chronic Lymphocytic Leukemia,” Oncogene, 22:8356-69 (2003).
Singer, M.J. et al., “Targeted Mutagenesis of DNA with Alkylating RecA Assisted Oligonucleotides,” Nucleic Acids Research, 27(24):e38i-viii (1999).
Bosanquet, A.G. et al., “Novel ex vivo Analysis of Nonclassical, Pleiotropic Drug Resistance and Collateral Sensitivity Induced by Therapy Provides a Rationale for Treatment Strategies in Chronic Lymphocytic Leukemia,” Blood, 87(5):1962-1971 (1996).
Christodoulopoulos, G. et al., “Potentiation of Chlorambucil Cytotoxicity in B-cell Chronic Lymphocytic Leukemia by Inhibition of DNA-dependent Protein Kinase Activity Using Wortmannin,” Cancer Research 58(9):1789-92 (1998).
Ioannidou, E. et al., “Synergistic Induction of Cytogenic Damage by Alkylating Antineoplastics and 5-Azacytidine in Human Lymphocytes,” Environmental and Molecular Mutagenesis, 14:6-12 (1989).
Harrap, K.R. et al., “The Alkylating Agent: Does a Knowledge of its Mode of Action Suggest Leads for Improving its Therapeutic Effectiveness?” Excerpta Medica International, 375:106-121 (1975).
Lohman, P.H.M., “Qualitative and Quantitative Procedures for Health Risk Assessment,” Mutation Research, 428:237-54 (1999).
Cruciani, G. et al., “Structure-based Rationalization of Antitumor Drugs Mechanism of Action by a MIF Approach,” European Journal of Medicinal Chemistry, 39:281-89 (2004).
Khan, S. et al., “Hepatocyte Toxicity of Mechlorethamine and Other Alkylating Anticancer Drugs,” Biochemical Pharmacology, 43(9): 1963-67 (1992).
Monti, E. et al., “Nitroxide TEMPOL Impairs Mitochondrial Function and Induces Apoptosis in HL60 Cells,” Journal of Cellular Biochemistry, 82:271-276 (2001).
Pietschmann, C., “Antibodies as Selective Weapons,” Livingbridges, 1:54-57 (2001).
Namiecinski, M. et al., “Cytotoxicity, Cytoprotection and Neurotoxicity of Novel Deprenyl-related Propargylamines, Stable Nitroxide Free Radicals, in vitro and in vivo,” In Vivo, 18(2):171-80 (2004)—Abstract.
Wu, Y. et al., “Cytotoxicity of a Newly Synthesized Nitroxide Derivative of 4-ferrocenecarboxyl-2,2,6,6-tetramethylpiperidine-1-oxyl in High Metastatic Lung Tumor Cells,” Pharmazie, 61(12):1028-33 (2006).
Black, S.M. et al., ȁ
Ba Yong
Mathias Errol V.
Aulakh Charanjit S
Gardner Diane L.
Mastermind IP Law P.C.
The Trustees of California State University
LandOfFree
Nitroxide free radical synergized antineoplastic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitroxide free radical synergized antineoplastic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitroxide free radical synergized antineoplastic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2704079